Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mymetics, a vaccine development company, has acquired a preventive malaria vaccine from Switzerland-based Pevion Biotech.
Subscribe to our email newsletter
The Pevion vaccine has successfully completed human clinical trial Phases I and II in Switzerland and in the UK, respectively, with only two of four contemplated antigens. The clinical trials are being conducted in connection with the application for approval of this vaccine under the EU regulations.
A Phase Ib clinical trial has been launched in Tanzania to extend the protocol to children and teenagers in a naturally endemic area. A new cycle of Phase I and II clinical trials with all four antigens is scheduled thereafter.
Christian Rochet, CEO and president of Mymetics, said: “We are pleased with this acquisition which allows us to start feeding a pipeline of products for the future, in addition to our preventive HIV/AIDS vaccine.”